Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | GJB2 | P29033 | 2/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.31 |
| ▸ | CDC25B | P30305 | 2/20 | 0.31 |
| ▸ | NT5E | P21589 | 1/20 | 0.31 |
| ▸ | SELP | P16109 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16367548 | 0.84 | SLC6A2 (0.35) | SLC6A2GJB2PTPN1CDC25BNT5E | |
| SCHEMBL17826458 | 0.83 | NT5E (0.36) | GJB2PTPN1CDC25BNT5ESELP | |
| SCHEMBL22168482 | 0.78 | PTPN1 (0.42) | GJB2PTPN1CDC25BNT5E | |
| SCHEMBL16772388 | 0.74 | SELP (0.39) | SLC6A2SELP | |
| SCHEMBL16772382 | 0.74 | SELP (0.39) | SLC6A2SELP | |
| SCHEMBL16772374 | 0.73 | SELP (0.32) | SELP | |
| SCHEMBL16772369 | 0.72 | SELP (0.35) | SELP | |
| SCHEMBL16367607 | 0.71 | MAPT (0.35) | — | |
| SCHEMBL17826455 | 0.71 | SSTR1 (0.39) | GJB2PTPN1CDC25BNT5ESELP | |
| SCHEMBL26452998 | 0.71 | SELP (0.37) | SLC6A2GJB2PTPN1CDC25BSELP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170368002-A1 | INKT CELL MODULATORS AND METHODS OF USING THE SAME | LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) | 2017-12-28 | — | — | US | disclosed |
| US-20160361280-A1 | INKT CELL MODULATORS AND METHODS OF USING THE SAME | LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) | 2016-12-15 | — | — | US | disclosed |
| US-20150010496-A1 | INKT CELL MODULATORS AND METHODS OF USING THE SAME | THE UNIVERSITY OF BIRMINGHAM (GB) | 2015-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160361280-A1 | INKT CELL MODULATORS AND METHODS OF USING THE SAME | PBK, NFATC1, UGCG | SLC6A2 4866/4885GJB2 4101/4885PTPN1 2748/4885 |
| US-20170368002-A1 | INKT CELL MODULATORS AND METHODS OF USING THE SAME | PBK, NFATC1, UGCG | SLC6A2 4866/4885GJB2 4101/4885PTPN1 2748/4885 |
| US-20150010496-A1 | INKT CELL MODULATORS AND METHODS OF USING THE SAME | PBK, NFATC1, UGCG | SLC6A2 4866/4885GJB2 4101/4885PTPN1 2748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.